Can immune cells predict herpesvirus danger in transplant patients?
NCT ID NCT05532540
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ rejection, these viruses can reactivate and cause serious infections. By analyzing blood samples from 80 liver transplant patients, researchers hope to understand which immune responses protect against these infections and identify those at highest risk, potentially guiding future treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- No drug or intervention is being tested; this is an observational study of immune responses.
- What this could lead to
- If successful, this could identify patients at high risk for herpesvirus infections and pave the way for new treatments to prevent CMV and VZV complications after liver transplant.
- What could go wrong
- This is an observational study, so it won't directly test any treatment. The findings may not immediately translate into new therapies, and the small sample size (80 participants) may limit how broadly the results apply.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Health Technology, Technical University of Denmark
Lyngby, 2800, Denmark
-
Department of Infectious Diseases, Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
-
Department of Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet
Copenhagen, 2100, Denmark
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a vaccine shield transplant patients from shingles?
- Can a helping hand ease the burden of pediatric liver transplants?
- Can a helping hand ease the leap to adult transplant care?
- Muscle quality on MRI may foretell liver transplant success
- Can specially grown immune cells from donors beat viruses that won't go away?
- Better crystal ball for liver crisis: new scores put to the test